1. Audit of medical (non-targeted) liver biopsy specimen quality, pathology reporting and effect on patient management
- Author
-
Prakash Konanahalli, Ewan Forrest, Sidhant Seth, M. Heydtmann, J. Morris, Karin A. Oien, and Gabriele Kohnen
- Subjects
Clinical audit ,medicine.medical_specialty ,Biopsy ,Audit ,Pathology and Forensic Medicine ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,medicine ,Humans ,Medical Audit ,medicine.diagnostic_test ,business.industry ,Liver Diseases ,General surgery ,General Medicine ,medicine.disease ,Patient management ,Pathologists ,Liver ,Specimen Quality ,030220 oncology & carcinogenesis ,Liver biopsy ,030211 gastroenterology & hepatology ,Biopsy, Large-Core Needle ,Image-Guided Biopsy ,business - Abstract
AimsTo evaluate our medical liver pathology practice and its influence on patient management, using audit templates published by the UK Royal College of Pathologists (RCPath).MethodsWe audited medical liver biopsies reported in our centre in 2019 using RCPath proformas. Data were collected from pathology reports and corresponding electronic patient record.Results60 cases were selected for audit from 135 eligible biopsies reported in 2019. 58/60 cases were core biopsies and 2/60 were laparoscopic wedge biopsies. 53/57 (93%) core biopsies with available data met RCPath adequacy criteria (length >15 mm and/or ≥6 portal tracts). Most reports (57/60; 95%) were judged to have helped patient management. 25/60 (42%) biopsy reports helped to clarify the clinical diagnosis and 48/60 (80%) led to altered management.ConclusionsWe demonstrate the utility of the RCPath audit templates, highlighting the clinical value of medical liver biopsies in the diagnostic work-up and management of patients with liver disease.
- Published
- 2021
- Full Text
- View/download PDF